The Next Big Thing In Biotech: Ligand, BioMarin & Sangamo
Nov 30, 2012 | 5:30 AM EST - 

Adam Feuerstein, Sr. Columnist for TheStreet, says Ligand, BioMarin and Sangamo are the next big things to watch in biotech.

Columnist Conversations

In travel status most of day but a quick missive before I head to the airport. Looks like after yesterday's m...
It does feel like the Saudis are making a deal to cut production as oil is even stronger than I thought ...
And QQQ -$0.45
I have shorted today's ramp into tomorrow's #. See next post.

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.